Medical Affairs
Medical Education Grant Breaches: A Case in Firewall Breakdown
The myth I keep hearing in Medical Affairs circles — usually whispered over conference coffee, sometimes shouted into a…
Just in
Medical Consulting
Medical Advisory Vetting: Evaluating Biopharma Consultants
We have all seen the moment. A boardroom falls quiet when someone asks, carefully, why a Phase II readout arrived three quarters…
Clinical Development
Project Optimus Dosing: What Regulators Actually Expect
dosing paradigm that anchored oncology drug development for decades is now the structural bottleneck. Maximum Tolerated Dose…
Medical Affairs
Scientific Communication Platforms: Practical Rollout
Every Medical Affairs leader I know has, at some point, stood in front of a cross-functional steering committee and declared the…
Pharmacovigilance
In-House vs Outsourced PV: Strategic Trade-Offs for MAHs
Every Marketing Authorisation Holder eventually arrives at the same crossroads: who actually carries the safety signal — your own…
Medical Consulting
Clinical Asset Diligence: A Biopharma Case Review
Approximately 70% of new drug candidates fail in Phase II, the stage at which proof of concept is tested in patients. Lack of…
Clinical Development
DSMB Stopping Boundaries: What Trial Teams Miss
A DSMB stopping boundary looks reassuring on paper. It has a p-value, an interim analysis time point, perhaps a neat table…
Regulatory Compliance
Pharma Employee Social Media: Where PMCPA Draws the Line
For many pharmaceutical employees, LinkedIn activity still feels like a private extension of professional life: a congratulatory…
Medical Affairs
MSL KPI Frameworks for Measuring Strategic Value
Ninety-two percent of organizations still evaluate Medical Science Liaison performance primarily through activity-based metrics…
Medical Consulting
Locum Medical Advisory vs Retained Consulting in Biopharma
The most expensive medical leadership gap in biopharma is rarely visible on the balance sheet. It appears as delayed decisions…
Clinical Development
Protocol Design Mistakes That Stall Phase 2 Trials
Seventy-six percent of clinical trials now require at least one substantial protocol amendment — up from 57% a decade ago. That…
Regulatory Compliance
Medical Signatory Review: Inside the ABPI Sign-Off
A medical signatory review is often treated as the final administrative step before a pharmaceutical asset can be issued. In…
Medical Affairs
Field Medical Insights: Why Qualitative Data Matters Now
A 2025 global survey of 1,023 medical affairs professionals across 63 countries recorded a structural contradiction at the core…
Pharmacovigilance
PSUR EURD Alignment: Practical Steps for MAH Compliance
The most expensive PSUR mistake is rarely a dramatic scientific failure. More often, it is a calendar failure dressed up as an…
Clinical Development
Adaptive vs Fixed Trial Design: Evaluating the Trade-Offs
A clinical trial can be statistically elegant and still be difficult for patients to live through. A fixed design gives the study…
Medical Affairs
Advisory Board Failures: A Medical Affairs Case Study
Sixty percent. That figure represents the proportion of total session time consumed by company slide presentations in a typical…
Pharmacovigilance
Pharmacovigilance System Master File Architecture
A Pharmacovigilance System Master File (PSMF) is not a static compliance dossier assembled for an inspection. It is the…
Pharmacovigilance
EudraVigilance Signal Detection: What MAHs Must Know
On 22 July 2025, Implementing Regulation (EU) 2025/1466 entered into force and brought the EudraVigilance signal detection pilot…
Medical Consulting
Fractional CMO Strategy: Actionable Steps for Biotechs
Organizations deploying fractional executive structures report leadership overhead cost reductions of 40% to 60% compared to…
Medical Affairs
Investigator-Initiated Studies: Internal Pharma Review
We have all seen it happen. A brilliant investigator approaches us at a medical conference, eyes bright with a research idea that…
Regulatory Compliance
Promotional Review Pitfalls: A PMCPA Case Study
The two-signature certification process is often presented as the last line of defence between compliant promotion and regulatory…
Clinical Development
Surrogate Endpoints vs Overall Survival: Protocol Strategy
Nearly three-quarters of randomized oncology trials that hit their primary surrogate endpoint never demonstrate an overall…
News
About
Elevating clinical practice and patient care.